Disparities in the enrollment to systemic therapy and survival for patients with multiple myeloma

Publication date: Available online 10 October 2020Source: Hematology/Oncology and Stem Cell TherapyAuthor(s): Thejus T. Jayakrishnan, Veli Bakalov, Zena Chahine, John Lister, Rodney E. Wegner, Santhosh Sadashiv
Source: Hematology Oncology and Stem Cell Therapy - Category: Cancer & Oncology Source Type: research

Related Links:

Conditions:   Plasma Cell Myeloma;   Recurrent Plasma Cell Myeloma;   Refractory Plasma Cell Myeloma Interventions:   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Biological: Astatine At 211 Anti-CD38 Monoclonal Antibody OKT10-B10;   Drug: Cyclophosphamide;   Drug: Fludarabine Phosphate;   Radiation: Total-Body Irradiation Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
rte S, Pignatti F Abstract The use of daratumumab in combination with established regimens for the treatment of newly diagnosed Multiple Myeloma (MM) has recently been authorised by the European Medicines Agency based on results from 3 separate phase 3 randomized, active controlled open label studies which have confirmed enhanced efficacy and tolerability in both transplant ineligible (MMY3008 and MMY 3007) and eligible patients (MMY3006), without compromising transplant ability. Trial MMY3008 showed an improvement in progression-free survival (PFS) when daratumumab was added to lenalidomide and dexamethasone comp...
Source: The Oncologist - Category: Cancer & Oncology Authors: Tags: Oncologist Source Type: research
This article has been retracted. Please see the retraction notice for more detail: https://doi.org/10.1007/s00520-020-05770-w.
Source: Supportive Care in Cancer - Category: Cancer & Oncology Source Type: research
Publication date: October 2020Source: Clinical Lymphoma Myeloma and Leukemia, Volume 20, Issue 10Author(s): Patrick Stelmach, Klaus Wethmar, Christoph Groth, Daniela V. Wenge, Jörn Albring, Jan-Henrik Mikesch, Christoph Schliemann, Christian Reicherts, Wolfgang E. Berdel, Georg Lenz, Matthias Stelljes
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Publication date: October 2020Source: Clinical Lymphoma Myeloma and Leukemia, Volume 20, Issue 10Author(s): Mahmut Yeral, Pelin Aytan, Burcu Gungor, Can Boga, Ali Unal, Yener Koc, Leylagul Kaynar, Nurhilal Buyukkurt, Bulent Eser, Hakan Ozdoğu
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Rationale: Reactivation of hepatitis B virus (HBV) after treatment with bortezomib-based regimens in HBV-positive patients with multiple myeloma (MM) has been reported in the past few years. Nevertheless, there is evidence of inhibition of HBV replication by bortezomib in transgenic mice. However, there is still no clinical evidence that bortezomib inhibits HBV. Patient concerns: A 55-year-old MM patient with a family history of MM, who was also a chronic HBV carrier, achieved HBV clearance after treatment with a bortezomib-based regimen in combination with anti-HBV drugs. Diagnoses: The diagnosis was MM with chron...
Source: Medicine - Category: Internal Medicine Tags: Research Article: Clinical Case Report Source Type: research
AbstractMultiple myeloma (MM) is an incurable cancer characterized by abnormal plasma cells in the bone marrow, resulting in increased risk of infection. Autologous stem cell transplant (ASCT) is the most effective treatment for MM, but successful transplant requires the patient and caregiver to learn and independently implement medical tasks. The Ready for Transplant (R4T) ethnographic-based formative evaluation includes evaluation of ongoing patient education and the addition of novel supplemental educational videos that patients can review before in-person transplant education. To evaluate R4T, a formative evaluation in...
Source: Journal of Cancer Education - Category: Cancer & Oncology Source Type: research
CONCLUSION: The etoposide and cyclophosphamide regimen could be an effective and safe method for mobilization in patients with multiple myeloma. PMID: 32971582 [PubMed - in process]
Source: Clinical and Investigative Medicine - Category: Biomedical Science Authors: Tags: Clin Invest Med Source Type: research
Authors: Gentile M, Morabito F, Martino M, Vigna E, Martino EA, Mendicino F, Martinelli G, Cerchione C Abstract Multiple myeloma (MM) represents the second-most common hematologic malignancy. In the 1980s, induction therapy with alkylating agents, such as anthracyclines and steroids, as well as high-dose chemotherapy followed by autologous stem cell transplantation were the main therapeutic approaches for MM. Since the introduction of more effective drugs, such as proteasome inhibitors, immunomodulatory drugs, monoclonal antibodies and histone deacetylase inhibitor, the new therapeutic algorithm allows of achieving...
Source: Panminerva Medica - Category: General Medicine Tags: Panminerva Med Source Type: research
Authors: Martino M, Paviglianiti A, Gentile M, Martinelli G, Cerchione C Abstract Multiple myeloma (MM) accounts for about 1.8% of all cancers and slightly over 17% of hematologic malignancies. Despite improvements in outcomes in recent years, currently, there is still no cure for this disease. Although allogeneic stem cell transplantation (Allo-SCT) is a potentially curative treatment, given the armamentarium of highly effective therapeutic options and a pipeline of novel agents, many opinion leaders sustain that there is no longer a role for this approach. Of note, several studies that did not include novel agent...
Source: Panminerva Medica - Category: General Medicine Tags: Panminerva Med Source Type: research
More News: Cancer & Oncology | Hematology | Myeloma | Stem Cell Therapy | Stem Cells